{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.3"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"12"}],"units":"Participants"}],"description":"Tumor assessment will be performed using RANO criteria for LGG.","groups":[{"description":"Participants with Low Grade Glioma.","id":"OG000","title":"Low Grade Glioma"}],"paramType":"NUMBER","populationDescription":"The safety evaluable population was defined as all participants who received at least one dose of study drug. For phase II, only one tumor type cohort was opened (LGG).","reportingStatus":"POSTED","timeFrame":"Baseline up to disease progression or death due to any cause, whichever occurs first (up to 5 years, 2 months)","title":"Percentage of Participants With Objective Response (CR or PR) as Determined by the Investigator Using RANO Criteria for Participants With LGG (Phase II)","type":"PRIMARY","unitOfMeasure":"Percentage of Participants"}